Brokers

Brokers Set Expectations for Hepion Pharmaceuticals, Inc.’s FY2022 Earnings (NASDAQ:HEPA)


Hepion Pharmaceuticals, Inc. (NASDAQ:HEPAGet Rating) – Cantor Fitzgerald raised their FY2022 earnings estimates for Hepion Pharmaceuticals in a report released on Wednesday, May 18th. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($0.49) per share for the year, up from their previous estimate of ($0.52). Cantor Fitzgerald currently has a “Overweight” rating and a $3.50 target price on the stock.

Other equities analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Hepion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 29th. Brookline Capital Management restated a “buy” rating on shares of Hepion Pharmaceuticals in a research report on Wednesday, January 26th.

HEPA stock opened at $0.75 on Monday. Hepion Pharmaceuticals has a 12 month low of $0.61 and a 12 month high of $2.32. The company has a fifty day moving average price of $1.01 and a 200 day moving average price of $1.11.

Large investors have recently bought and sold shares of the company. State Street Corp grew its stake in Hepion Pharmaceuticals by 8.1% in the 1st quarter. State Street Corp now owns 348,910 shares of the company’s stock valued at $450,000 after acquiring an additional 26,194 shares during the last quarter. Renaissance Technologies LLC grew its stake in Hepion Pharmaceuticals by 151.7% in the 1st quarter. Renaissance Technologies LLC now owns 126,600 shares of the company’s stock valued at $163,000 after acquiring an additional 76,300 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in Hepion Pharmaceuticals by 204.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 35,139 shares of the company’s stock valued at $40,000 after acquiring an additional 23,584 shares during the last quarter. Virtu Financial LLC acquired a new stake in Hepion Pharmaceuticals in the 4th quarter valued at about $57,000. Finally, Envestnet Asset Management Inc. grew its stake in Hepion Pharmaceuticals by 87.5% in the 4th quarter. Envestnet Asset Management Inc. now owns 72,027 shares of the company’s stock valued at $82,000 after acquiring an additional 33,609 shares during the last quarter. 11.57% of the stock is currently owned by institutional investors and hedge funds.

About Hepion Pharmaceuticals (Get Rating)

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease.

Recommended Stories



Receive News & Ratings for Hepion Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.